Israel Englander’s Intellia Therapeutics NTLA Stock Holding History

Israel Englander’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-130,500	Closed	-$6.75M	–	7362
2022 Q2	$6.75M	Buy	130,500 +80,500	+161%	+$4.09M	﹤0.01%	2480
2022 Q1	$3.63M	Buy	50,000 +45,000	+900%	+$3.81M	﹤0.01%	3288
2021 Q4	$591K	Buy	+5,000	New	+$626K	﹤0.01%	4899
2021 Q3	–	Sell	-103,800	Closed	-$16.8M	–	7099
2021 Q2	$16.8M	Buy	103,800 +78,600	+312%	+$6.12M	0.01%	1362
2021 Q1	$2.02M	Buy	25,200 +20,200	+404%	+$1.36M	﹤0.01%	3525
2020 Q4	$272K	Buy	+5,000	New	+$182K	﹤0.01%	4614

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Israel Englander's NTLA Position: Q2 2026 in Review

Israel Englander increased its Intellia Therapeutics (NTLA) stake by 596% in Q2 2026, buying an estimated $5.89M and bringing the position to 491,226 shares worth $8.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

Israel Englander first reported a position in NTLA in Q3 2016 and has held it in 34 quarters since. The position peaked at $36.4M in Q1 2022. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Israel Englander held 491,226 shares of Intellia Therapeutics worth $8.31M as of Q2 2026.
Israel Englander bought 420,667 Intellia Therapeutics shares in Q2 2026, an estimated $5.89M.
Intellia Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2486 holding.
Israel Englander first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 34 quarters since.
Israel Englander's Intellia Therapeutics position peaked at $36.4M in Q1 2022.
326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.